Jefferies initiated coverage of Insmed (INSM) with a Buy rating and $105 price target The company’s “first-in-disease status”, strong clinical profile, and enthusiasm among key opinion leaders should assure a rapid launch for its brensocatib drub, which is a “potential megablockbuster” bronchiectasis treatment, the analyst tells investors in a research note. Insmed’s commercial asset Arikayce is also likely to expand to first-line MAC lung disease, Jefferies added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Promising Financial Performance and Pipeline Developments Drive Buy Rating
- Insmed’s Growth Potential: Catalysts and Strategic Developments Supporting a Buy Rating
- Insmed price target lowered to $109 from $110 at UBS
- Insmed Reports Strong Q1 2025 Growth and Progress
- Insmed’s Promising Pipeline and Strong Financials Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue